The long-term goal of this proposal is to correct an inborn error of metabolism, citrullinemia, by hepatocyte gene therapy using the adenoviral delivery system. Citrullinemia, an autosomal recessive enzymatic deficiency of argininosuccinate synthetase (ASS), is representative of the group of urea cycle defects. They present in the neonatal period with hyperammonemic coma and result in long-term neurological and developmental deficits. Plasma, metabolites, ammonia, and citrulline can be easily quantitated to monitor the efficacy of therapeutic intervention, and both murine and bovine models are available. Protocols derived from this study are expected to be applicable to other genetic disorders characterized by primary metabolic dysfunction of hepatocytes. Transient correction of the ASS deficiency will first be attempted by in vivo transduction of hepatocytes after intravenous delivery of an E1-deleted type 5 adenovirus (Ad-ASS) into a neonatal murine model. Once the optimal dose and pattern of delivery is determined and efficacy is established by direct enzymatic assay of liver isolates and by achieving normalized growth rates and prolonged survival, the protocol will be scaled up and applied to the larger bovine model. At first, a recombinant adenovirus (Ad-AAT) expressing a serum reported gene product, alpha-antitrypsin (alpha1AT), will be delivered intravenously into normal neonatal calves. The extent, efficacy, and kinetics of heterologous gene expression and morbidity associated with infection will be determined by serial measurements of serum alpha1AT, adenovirus specific neutralizing antibodies, blood chemistries, an immuno-histologic analysis of liver isolates. Subsequently, Ad-ASS will be delivered into citrullinemic newborn calves using optimized dosage and delivery protocols. Once transient correction of the metabolic defect is demonstrated in the bovine model, human trials will be proposed. Even a transient correction may abbreviate the hyperammonemic state and reduce long-term central nervous system morbidity. Concurrent studies directed at minimizing the role of host immune response in terminating the initial period of heterologous gene expression and in limiting subsequent reinfection will be carried out in the bovine model. The ability to induce immune tolerance will be investigated by delivering the reporter construct Ad-AAT in the neonatal and in utero period. In addition, new adenoviral vectors mutated in the E2a and E4 domains and designed to minimize adenoviral protein expression and host antigen presentation will be tested.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK002407-02
Application #
2377691
Study Section
Special Emphasis Panel (SRC)
Project Start
1995-09-30
Project End
2001-02-28
Budget Start
1997-03-01
Budget End
1998-02-28
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Seymour, Michelle L; Binion, David G; Compton, Steven J et al. (2005) Expression of proteinase-activated receptor 2 on human primary gastrointestinal myofibroblasts and stimulation of prostaglandin synthesis. Can J Physiol Pharmacol 83:605-16
Ogawa, Hitoshi; Rafiee, Parvaneh; Heidemann, Jan et al. (2003) Mechanisms of endotoxin tolerance in human intestinal microvascular endothelial cells. J Immunol 170:5956-64
Ogawa, Hitoshi; Rafiee, Parvaneh; Fisher, Pamela J et al. (2003) Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem Biophys Res Commun 309:512-9
Ogawa, Hitoshi; Rafiee, Parvaneh; Fisher, Pamela J et al. (2003) Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition. FEBS Lett 554:88-94
Strauch, U G; Mueller, R C; Li, X Y et al. (2001) Integrin alpha E(CD103)beta 7 mediates adhesion to intestinal microvascular endothelial cell lines via an E-cadherin-independent interaction. J Immunol 166:3506-14
Lee, B; Yu, H; Jahoor, F et al. (2000) In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle. Proc Natl Acad Sci U S A 97:8021-6
Lee, B; Dennis, J A; Healy, P J et al. (1999) Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia. Proc Natl Acad Sci U S A 96:3981-6
O'Neal, W K; Zhou, H; Morral, N et al. (1998) Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum Gene Ther 9:1587-98
Patejunas, G; Lee, B; Dennis, J A et al. (1998) Evaluation of gene therapy for citrullinaemia using murine and bovine models. J Inherit Metab Dis 21 Suppl 1:138-50